Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study
作者： Sung Ryul Shim , Jae Heon Kim , In Ho Chang , In Soo Shin , Sung Dong Hwang
DOI: 10.3349/YMJ.2016.57.2.407
关键词: Urology 、 Alpha (ethology) 、 First line treatment 、 Pharmacology 、 Low dose 、 Tamsulosin 、 Meta-analysis 、 Medicine 、 Adrenergic alpha-Antagonists
摘要: Purpose Tamsulosin 0.2 mg is used widely in Asian people, but the low dose has been studied less than tamsulosin 0.4 or other alpha blockers of standard dose. This study investigated efficacy and safety by a meta-analysis meta-regression.
komci.org参考文章(45)
Yan Jung Na, F.-L. Gu, Y. L. Guo, Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. Journal of Medicine. ,vol. 29, pp. 289- 304 ,(1998)
Jian-Tang Su, Hong-Fei Wu, Xiao-Bing Ju, The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia National journal of andrology. ,vol. 8, pp. 286- 288 ,(2002)
Choal Hee Park, Hyuk Soo Chang, Bong Ryul Oh, Hyung Jee Kim, Chong Koo Sul, Sung Kwang Chung, Se Il Jung, Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study. Clinical Drug Investigation. ,vol. 24, pp. 41- 47 ,(2004) , 10.2165/00044011-200424010-00005
J. H. Kim, S. R. Shim, W. J. Lee, H. J. Kim, S.-S. Kwon, J. H. Bae, Sociodemographic and lifestyle factors affecting the self-perception period of lower urinary tract symptoms of international prostate symptom score items International Journal of Clinical Practice. ,vol. 66, pp. 1216- 1223 ,(2012) , 10.1111/J.1742-1241.2012.02988.X
Larry V. Hedges, Harris Cooper, Jeffrey C. Valentine, The Handbook of Research Synthesis and Meta-Analysis ,(2019)
A. Okuyama, S. Ozono, Y. Hirao, E. Okajima, K. Yamamoto, T. Kishimoto, Y. Park, T. Kurita, H. Okada, S. Kamidono, T. Yoshioka, A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients BJUI. ,vol. 85, pp. 676- 681 ,(2001) , 10.1046/J.1464-410X.2000.00608.X
U. Jonas, C. C. Schulman, M. J. Speakman, J. Cortvriend, S. Vaage, T. M. T. W. Lock, Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. European Urology. ,vol. 29, pp. 145- 154 ,(1996)
Hong-Jeng Yu, Alex Tong-Long Lin, Stephen Shei-Dei Yang, Ke-Hung Tsui, Hsi-Chin Wu, Chen-Li Cheng, Hong-Lin Cheng, Tony T. Wu, Po-Hui Chiang, Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) BJUI. ,vol. 108, pp. 1843- 1848 ,(2011) , 10.1111/J.1464-410X.2011.10233.X
J. H. Kim, J. Y. Park, M. M. Oh, J. G. Lee, S.-S. Kwon, J. H. Bae, Treatment satisfaction with low‐dose tamsulosin for symptomatic benign prostatic hyperplasia: results from a multicentre cross‐sectional survey International Journal of Clinical Practice. ,vol. 66, pp. 1209- 1215 ,(2012) , 10.1111/J.1742-1241.2012.02985.X
Herbert Lepor, Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial Urology. ,vol. 51, pp. 901- 906 ,(1998) , 10.1016/S0090-4295(98)00127-7